NCT02659241 - Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Fallopian Tube CarcinomaAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaCarcinomatosisFallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaStage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7

Interventions

DRUG

Adavosertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (8)

77024

Memorial Hermann Memorial City Medical Center, Houston

77030

M D Anderson Cancer Center, Houston

77054

The Woman's Hospital of Texas, Houston

77079

MD Anderson West Houston, Houston

77384

MD Anderson in The Woodlands, Conroe

77478

MD Anderson in Sugar Land, Sugar Land

77573

MD Anderson League City, League City

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER